medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2010, Número 2

<< Anterior Siguiente >>

Arch Neurocien 2010; 15 (2)


Sueño y enfermedad de Parkinson

San-Juan OD, Castillo CJD

Idioma: Español
Referencias bibliográficas: 80
Paginas: 93-100
Archivo PDF: 96.10 Kb.


RESUMEN

El sueño es un componente vital definido con base al comportamiento individual y a la actividad eléctrica cerebral, se ha visto una relación entre las enfermedades neurodegenerativas como la enfermedad de Parkinson y trastornos del sueño. Desarrollo: en esta revisión se analizaron datos de varios trastornos del sueño y su relación con la enfermedad de Parkinson que han sido publicados en diversos artículos; los trastornos estudiados son: insomnio, alteraciones del ritmo circadiano, apnea del sueño, síndrome de piernas inquietas y trastorno de movimientos periódicos de las extremidades, desorden del comportamiento del REM; así como, también se revisan los efectos del tratamiento antiparkinsoniano en los trastornos del sueño. Conclusiones: los trastornos del sueño se encuentran con frecuencia asociados a la enfermedad de Parkinson, constituyendo una comorbilidad importante. Los trastornos del sueño podrían predecir la aparición a mediano y largo plazo de la enfermedad de Parkinson.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Markov D, Goldman M. Normal sleep and circadian rhythms: neurobiologic mechanisms underlying sleep and wakefulness. Psychiatr Clin North Am 2006;29(4):841-53.

  2. Chokroverty S. An overview of normal sleep. In Chokroverty S, Wayne AH, Walters AS, ed. Sleep and movement disorders. Butterworth Heinemann Philadelphia 2003.

  3. Sinton CM, McCarley RW. Neurophysiological mechanisms of sleep and wakefulness: a question of balance. Semin Neurol 2004;24:211-23.

  4. Roth T, Roehrs T. Sleep organization and regulation. Neurology 2000;54: (Suppl 1): S2-S7.

  5. Roth T. Characteristics and determinants of normal sleep. J Clin Psychiatry 2004;65. (Suppl 16): 8-11.

  6. Gooneratne NS, Weaver TE, Cater JR. Functional outcomes of excessive daytime sleepiness in older adults. J Am Geriatr Soc 2003; 51:642-9.

  7. Bhatt MH, Podder N, Chokroverty S. Sleep and neurodegenerative diseases. Semin Neurol 2005;25(1):39-51.

  8. Tandberg E, Larsen JP, Karlsen K.A community-based study of sleep disorders in patients with Parkinson’s disease. Mov Disord 1998; Nov;13(6):895-9.

  9. Karlsen KH, Tandberg E, Arsland D, Larsen JP. Health related quality of life in Parkinson’s disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry 2000;(5):584-9.

  10. Foley DJ, Monjan A, Simonsick EM, Wallace RB, Blazer DG. Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years. Sleep 1999;22 Suppl 2:S366-72.

  11. Goetz CG, Wuu J, Curgian LM, Leurgans S. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology 2005;64(1):81-6.

  12. Gjerstad MD, Wentzel-Larsen T, Aarsland D, Larsen JP. Insomnia in Parkinson’s disease: frequency and progression over time. J Neurol Neurosurg Psychiatry 2007;78(5):476-9.

  13. Wetter TC, Collado-Seidel V, Pollmacher T, Yassouridis A, Trenkwalder C. Sleep and periodic leg movement patterns in drug-free patients with Parkinson’s disease and multiple system atrophy. Sleep 2000;23(3):361-7.

  14. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson’s disease patients with treatment-induced hallucinations. Ann Neurol 1993;34(5):710-4.

  15. Arnulf I, Konofal E, Merino-Andreu M, Houeto JL, Mesnage V, Welter ML, et al. Parkinson’s disease and sleepiness: an integral part of PD. Neurology 2002;(7):1019-24.

  16. Iranzo A, Valldeoriola F, Santamaria J, Tolosa E, Rumia J. Sleep symptoms and polysomnographic architecture in advanced Parkinson’s disease after chronic bilateral subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002;72(5):661-4.

  17. Young A, Home M, Churchward T, Freezer N, Holmes P, Ho M. Comparison of sleep disturbance in mild versus severe Parkinson’s disease. Sleep 2002;(5):573-7.

  18. Adler CH, Thorpy MJ. Sleep issues in Parkinson’s disease. Neurology 2005;(12 Suppl 3):S12-20.

  19. Freeman A, Ciliax B, Bakay R, Daley J, Miller RD, Keating G, et al. Nigrostriatal collaterals to thalamus degenerate in parkinsonian animal models. Ann Neurol 2001;50(3):321-9.

  20. Rye DB, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology 2002;(3):341-6.

  21. Agid Y. Parkinson’s disease: pathophysiology. Lancet 1991; 337:1321-4.

  22. Luppi PH, Gervasoni D, Verret L, Goutagny R, Peyron C, Salvert D, et al. Paradoxical (REM) sleep genesis: the switch from an aminergic-cholinergic to a GABAergic-glutamatergic hypothesis. J Physiol Paris 2006;(5-6):271-83.

  23. Lu J, Sherman D, Devor M, Saper CB. A putative flip-flop switch for control of REM sleep. Nature 2006;(7093):589-94.

  24. Lee MS, Rinne JO, Marsden CD. The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med J 2000;41:167-84.

  25. Wetter TC, Trenkwalder C, Gershanik O, Hogl B. Polysomnographic measures in Parkinson’s disease: a comparison between patients with and without REM sleep disturbances. Wien Klin Wochenschr 2001; 113:249-53.

  26. Ancoli-Israel S, Martin JL. Insomnia and daytime napping in older adults. J Clin Sleep Med 2006;2(3):333-42.

  27. Neckelmann D, Mykletun A, Dahl AA. Chronic insomnia as a risk factor for developing anxiety and depression. Sleep 2007; 30(7):873-80.

  28. Becker PM. Insomnia: prevalence, impact, pathogenesis, differential diagnosis, and evaluation. Psychiatr Clin North Am 2006;29(4):855-70.

  29. Kunz D, Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord 1999;14:507-11.

  30. García Ruiz PJ. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson’s disease. Mov Disord 2006; 21(5):727-8.

  31. Bruguerolle B, Simon N. Biologic rhythms and Parkinson’s disease: a chronopharmacologic approach to considering fluctuations in function. Clin Neuropharmacol 2002;25:194-201.

  32. Bordet R, Devos D, Brique S, Touitou Y, Guieu JD, Libersa C, et al. Study of circadian melatonin secretion pattern at different stages of Parkinson’s disease. Clin Neuropharmacol 2003;26(2):65-72.

  33. Diederich NJ, Vaillant M, Leischen M, Mancuso G, Golinval S, Nati R, et al. Sleep apnea syndrome in Parkinson’s disease. A case-control study in 49 patients. Mov Disord 2005;20(11):1413-8.

  34. Maria B, Sophia S, Michalis M, Charalampos L, Andreas P, John ME, et al. Sleep breathing disorders in patients with idiopathic Parkinson’s disease. Respir Med 2003;97(10):1151-7.

  35. Wolkove N, Elkholy O, Baltzan M, Palayew M. Sleep and aging: 2. Management of sleep disorders in older people. CMAJ 2007; 176(10):1449-54.

  36. Shochat T, Pillar G. Sleep apnoea in the older adult: pathophysiology, epidemiology, consequences and management. Drugs Aging 2003;20:551-60.

  37. Quinnell TG, Smith IE. Obstructive sleep apnea in the elderly: recognition and management considerations. Drugs Aging 2004; 21:307-22.

  38. Ekbom KA. Restless legs syndrome. Neurology 1960;10:868-73.

  39. Trenkwalder C, Walters AS, Hening W. Periodic limb movements and restless legs syndrome. Neurol Clin 1996;14:629-50.

  40. Tan EK. Restless legs syndrome and Parkinson’s disease: is there an etiologic link? J Neurol 2006;253(Suppl 7):33-37.

  41. Loo HV, Tan EK. J Case-control study of restless legs syndrome and quality of sleep in Parkinson’s disease. Neurol Sci 2008;266 (1-2):145-9.

  42. Vilariño-Güell C, Soto AI, Young JE, Lin SC, Uitti RJ, Wszolek ZK, et al. Susceptibility genes for restless legs syndrome are not associated with Parkinson disease. Neurology 2008;71(3):222-3.

  43. Sforza E, Krieger J, Petiau C. REM sleep behavior disorder: clinical and physiopathological findings. Sleep Med Rev 1997;1:57-69.

  44. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000;123:331-9.

  45. Wolkove N, Elkholy O, Baltzan M, Palayew M. Sleep and aging: 1. Sleep disorders commonly found in older people. CMAJ 2007; 176(9):1299-304.

  46. Hickey MG, Demaerschalk BM, Caselli RJ, Parish JM, Wingerchuk DM. «Idiopathic» rapid-eye-movement (REM) sleep behavior disorder is associated with future development of neurodegenerative diseases. Neurologist 2007;13(2):98-101.

  47. Gagnon JF, Bedard MA, Fantini ML. REM sleep behavior disorder and REM sleep without atonia in Parkinson’s disease. Neurology 2002;59:585-9.

  48. De Cock VC, Vidailhet M, Leu S, Texeira A, Apartis E, Elbaz A, et al.Restoration of normal motor control in Parkinson’s disease during REM sleep. Brain 2007;130(Pt 2):450-6.

  49. Souques M. Rapport sur les syndrome parkinsoniens. Séance du 3–4. Rev Neurol 1921;1:534.

  50. Gjerstad MD, Boeve B, Wentzel-Larsen T, Aarsland D, Larsen JP. Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson’s disease over time. J Neurol Neurosurg Psychiatry 2008;79(4):387-91.

  51. Garcia-Borreguero D, Caminero AB, de la Llave Y. Decreased phasic EMG activity during rapid eye movement sleep in treatment naý¨ve Parkinson’s disease: effects of treatment with levodopa and progression of illness. Mov Disord 2002;17:934-41.

  52. Eisensehr I, von Lindeiner H, Jaüger M, Noachtar S. REM sleep behavior disorder in sleep-disordered patients with versus without Parkinson’s disease: is there a need for polysomnography? J Neurol Sci 2001;186:7-11.

  53. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003;4:281-4.

  54. Takeuchi N, Uchimura N, Hashizume Y. Meltonin therapy for REM sleep behavior disorder. Psychiatry Clin Neurosci 2001;55:267-9.

  55. Dagan Y. Circadian rhythm sleep disorders (CRSD). Sleep Med Rev 2002;6:45-54.

  56. Fukuda N, Kobayashi R, Kohsaka M. Effects of bright light at lunchtime on sleep in patients in a geriatric hospital II. Psychiatry Clin Neurosci 2001;55:291-3.

  57. Happe S, Ludemann P, Berger K; FAQT study investigators. The association between disease severity and sleep-related problems in patients with Parkinson’s disease. Neuropsychobiology 2002;46(2):90-6.

  58. Ebrahim IO, Peacock KW. REM sleep behavior disorder—psychiatric presentations: a case series from the United Kingdom. J Clin Sleep Med 2005;1(1):43-7.

  59. Miller KM, Okun MS, Fernandez HF, Jacobson CE 4th, Rodriguez RL, Bowers D. Depression symptoms in movement disorders: comparing Parkinson’s disease, dystonia, and essential tremor. Mov Disord 2007;22(5):666-72.

  60. Borek LL, Kohn R, Friedman JH. Mood and sleep in Parkinson’s disease. J Clin Psychiatry 2006;(6):958-63.

  61. Bronnick K, Aarsland D, Larsen JP. Neuropsychiatric disturbances in Parkinson’s disease clusters in five groups with different prevalence of dementia. Acta Psychiatr Scand 2005;112(3):201-7.

  62. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. Patient-reported autonomic symptoms in Parkinson disease. Neurology 2007;69(4):333-41.

  63. Shulman LM, Wen X, Weiner WJ, Bateman D, Minagar A, Duncan R, et al. Acupuncture therapy for the symptoms of Parkinson’s disease. Mov Disord 2002;17(4):799-802.

  64. Reuter I, Ellis CM, Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson’s disease and restless legs syndrome. Acta Neurol Scand 1999;100(3):163-7.

  65. Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson’s disease. From description to etiology. J Neurol 2005;252(7):753-64.

  66. Chou KL, Messing S, Oakes D, Feldman PD, Breier A, Friedman JH. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 2005;28(5):215-9.

  67. Oved D, Ziv I, Treves TA, Paleacu D, Melamed E, Djaldetti R.Effect of dopamine agonists on fatigue and somnolence in Parkinson’s disease. Mov Disord 2006;21(8):1257-61.

  68. Homann CN, Wenzel K, Suppan K, Ivanic G, Kriechbaum N, Crevenna R, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ 2002;324(7352):1483-7.

  69. Gomez-Esteban JC, Zarranz JJ, Lezcano E, Velasco F, Ciordia R, Rouco I, et al. Sleep complaints and their relation with drug treatment in patients suffering from Parkinson’s disease. Mov Disord 2006;21(7):983-8.

  70. Hublin C, Partinen M, Heinonen EH, Puukka P, Salmi T. Selegiline in the treatment of narcolepsy. Neurology 1994;44:2095-101.

  71. Louden MB, Morehead MA, Schmidt HS. Activation by selegiline (Eldepryle) of REM sleep behavior disorder in parkinsonism. W V Med J 1995;91(3):101.

  72. Perry EK, Perry RH. Acetylcholine and hallucinations: diseaserelated consciousness. Brain Cogn 1995;28(3):240-58.

  73. Schafer D, Greulich W. Effects of parkinsonian medication on sleep. J Neurol 2000;247 (Suppl 4:IV)24-7.

  74. Wegelin J, McNamara P, Durso R, Brown A, McLaren D. Correlates of excessive daytime sleepiness in Parkinson’s disease. Parkinsonism Relat Disord 2005;11(7):441-8.

  75. Shpirer I, Miniovitz A, Klein C, Goldstein R, Prokhorov T, Theitler J, et al. Excessive daytime sleepiness in patients with Parkinson’s disease: a polysomnography study. Mov Disord 2006;21(9):1432-8.

  76. Cicolin A, Lopiano L, Zibetti M, Torre E, Tavella A, Guastamacchia G, et al. Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients. Sleep Med 2004;5(2):207-10.

  77. Lyons KE, Pahwa R. Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning




2020     |     www.medigraphic.com